

Commitee Members EIC Accelerator Programme Horizon Europe

Murcia, Spain, June 30, 2025

Dear Committee of the EIC Accelerator Programme:

The **Martín Álvarez Muelas Foundation** is a patient advocacy organization committed to supporting research and innovation that can bring meaningful improvements to the lives of patients and their families. In this regard, we wish to express our support for Gate2Brain's mission and technology.

**Gate2Brain**, S.L. is a biotechnology company that emerged in part from pediatric cancer research at the Sant Joan de Déu (SJD) Hospital in Barcelona, Spain. Our association collaborates with the research team at the SJD Hospital.

Gate2Brain develops therapeutics designed to cross the blood-brain barrier, a critical challenge for treating central nervous system diseases, especially pediatric brain tumors. The lead candidate of the company is G2B-002 and it targets pediatric-type diffuse high-grade gliomas, a condition with dismal prognosis and no curative treatment.

As a patient organization, we are particularly encouraged by Gate2Brain's success in the competitive European EIC Accelerator program. We greatly value Gate2Brain's commitment to combating childhood diseases and its focus on innovation in drug delivery. The development of solutions like G2B-002 represents hope for families facing these diagnoses and a potential shift in how treatments can reach the brain effectively.

The Martín Álvarez Muelas Foundation is firmly committed to the fight against pediatric cancer and DIPG, supporting SJD Hospital in this research.

We understand that Gate2Brain is approaching key milestones within the EIC Accelerator programme, and we are following this progress with great interest. We believe that initiatives such as theirs deserve recognition and support, as they align with our mission to advocate for better outcomes and access to new therapies for all patients.

Please consider this letter as a formal expression of our support for Gate2Brain's work. While this letter does not imply financial commitment or formal partnership, we

remain open to ongoing dialogue and to providing patient perspectives that may enrich the development process.

Sincerely,

Isabel Muelas President Fundación Martín Álvarez Muelas G13863808 Número registro 228 www.fundacionmartin.org